Skip to main content
SpringerLink
Log in

Nanoparticle-Mediated Endothelial Cell-Selective Drug Delivery System

  • Chapter
  • First Online:
Book cover Therapeutic Angiogenesis

Abstract

Peripheral arterial disease (PAD) causes peripheral tissue ischemia, resulting in skin ulceration, gangrene, and limb amputation. The therapeutic goal is restoration of blood supply, and various treatments including exercise, medical therapy, and surgical revascularization are performed. The prognosis of critical limb ischemia, however, is still unsatisfactory, and there are unmet needs in developing novel therapeutics. We have been developing novel nanotechnology-based drug delivery system aiming efficient angiogenesis by delivering of HMG-CoA reductase inhibitor (statin) to endothelium. In this chapter, we summarized current developing status of nanotechnology-based drug delivery system including animal experiments and ongoing clinical trials (CLINICAL TRIAL REGISTRATION NUMBER: UMIN000008011).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570–81.

    Article  CAS  PubMed  Google Scholar 

  2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74. doi:10.1038/nature01323.

    Article  CAS  PubMed  Google Scholar 

  3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl):S5–67. doi:10.1016/j.jvs.2006.12.037.

    Article  PubMed  Google Scholar 

  4. Steg PG, Bhatt DL, Wilson PW, D’Agostino Sr R, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–206. doi:10.1001/jama.297.11.1197.

    Article  CAS  PubMed  Google Scholar 

  5. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47(10):1255–6.

    Article  CAS  PubMed  Google Scholar 

  6. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–6. doi:10.1056/NEJM199202063260605.

    Article  CAS  PubMed  Google Scholar 

  7. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–654. doi:10.1161/CIRCULATIONAHA.106.174526.

    Article  PubMed  Google Scholar 

  8. Daskalopoulou M, George J, Walters K, Osborn DP, Batty GD, Stogiannis D, et al. Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: data linkage study of 1.9 million women and men. PLoS One. 2016;11(4):e0153838. doi:10.1371/journal.pone.0153838.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Gardner AW, Waldstein SR, Montgomery PS, Zhao YD. Effect of cognitive status on exercise performance and quality of life in patients with symptomatic peripheral artery disease. J Vasc Surg. 2016;63(1):98–104. doi:10.1016/j.jvs.2015.08.064.

    Article  PubMed  Google Scholar 

  10. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712–9.

    Article  CAS  PubMed  Google Scholar 

  11. Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv. 2009;2(4):277–83. doi:10.1016/j.jcin.2008.08.023.

    Article  PubMed  Google Scholar 

  12. Kitamoto S, Nakano K, Hirouchi Y, Kohjimoto Y, Kitajima S, Usui M, et al. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol. 2004;24(8):1522–8. doi:10.1161/01.ATV.0000134518.27241.da.

    Article  CAS  PubMed  Google Scholar 

  13. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001;108(3):399–405. doi:10.1172/jci13131.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Altieri DC. Statins’ benefits begin to sprout. J Clin Invest. 2001;108(3):365–6. doi:10.1172/JCI13556.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J. 2001;15(13):2530–2. doi:10.1096/fj.01-0415fje.

    CAS  PubMed  Google Scholar 

  16. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004–10. doi:10.1038/79510.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ikeda G, Matoba T, Nakano Y, Nagaoka K, Ishikita A, Nakano K, et al. Nanoparticle-mediated targeting of cyclosporine A enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci Rep. 2016;6:20467. doi:10.1038/srep20467.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Katsuki S, Matoba T, Nakashiro S, Sato K, Koga J, Nakano K, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilization/rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation. 2014;129(8):896–906. doi:10.1161/CIRCULATIONAHA.113.002870.

    Article  CAS  PubMed  Google Scholar 

  19. Kimura S, Egashira K, Chen L, Nakano K, Iwata E, Miyagawa M, et al. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension. 2009;53(5):877–83. doi:10.1161/HYPERTENSIONAHA.108.121418.

    Article  CAS  PubMed  Google Scholar 

  20. Kimura S, Egashira K, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, et al. Local delivery of imatinib mesylate (STI571)-incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation. 2008;118(14 Suppl):S65–70. doi:10.1161/CIRCULATIONAHA.107.740613.

    Article  CAS  PubMed  Google Scholar 

  21. Koga JI, Matoba T, Egashira K. Anti-inflammatory nanoparticle for prevention of atherosclerotic vascular diseases. J Atheroscler Thromb. 2016;23(7):757–65. doi:10.5551/jat.35113.

    Article  PubMed  Google Scholar 

  22. Nagaoka K, Matoba T, Mao Y, Nakano Y, Ikeda G, Egusa S, et al. A new therapeutic modality for acute myocardial infarction: nanoparticle-mediated delivery of pitavastatin induces cardioprotection from ischemia-reperfusion injury via activation of PI3K/Akt pathway and anti-inflammation in a rat model. PLoS One. 2015;10(7):e0132451. doi:10.1371/journal.pone.0132451.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9(4):325–41. doi:10.1586/erm.09.15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tsukie N, Nakano K, Matoba T, Masuda S, Iwata E, Miyagawa M, et al. Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J Atheroscler Thromb. 2013;20(1):32–45.

    Article  CAS  PubMed  Google Scholar 

  25. Kubo M, Egashira K, Inoue T, Koga J, Oda S, Chen L, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol. 2009;29(6):796–801. doi:10.1161/ATVBAHA.108.182584.

    Article  CAS  PubMed  Google Scholar 

  26. Oda S, Nagahama R, Nakano K, Matoba T, Kubo M, Sunagawa K, et al. Nanoparticle-mediated endothelial cell-selective delivery of pitavastatin induces functional collateral arteries (therapeutic arteriogenesis) in a rabbit model of chronic hind limb ischemia. J Vasc Surg. 2010;52(2):412–20. doi:10.1016/j.jvs.2010.03.020.

    Article  PubMed  Google Scholar 

  27. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease. Part I: angiogenic cytokines. Circulation. 2004;109(21):2487–91. doi:10.1161/01.CIR.0000128595.79378.FA.

    Article  PubMed  Google Scholar 

  28. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: part II: cell-based therapies. Circulation. 2004;109(22):2692–7. doi:10.1161/01.CIR.0000128596.49339.05.

    Article  PubMed  Google Scholar 

  29. Baumgartner I, Isner JM. Stimulation of peripheral angiogenesis by vascular endothelial growth factor (VEGF). Vasa. 1998;27(4):201–6.

    CAS  PubMed  Google Scholar 

  30. Marui A, Tabata Y, Kojima S, Yamamoto M, Tambara K, Nishina T, et al. A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J. 2007;71(8):1181–6.

    Article  CAS  PubMed  Google Scholar 

  31. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391–7. doi:10.1172/JCI13152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

These studies are supported partly by Center for Clinical and Translational Research Kyushu University Hospital.

NK-104-NP investigators: principal investigator, T Matsumoto, MD, PhD.. Co-investigators: Y Maehara, MD, PhD.; T Furuyama, MD, PhD.; R Kyuragi, MD, PhD.; Y Aoyagi, MD; Y Matsubara, MD; K Inoue, MD; S Tanaka, MD; R Yoshiga, MD; K Yoshiya, MD (Department of Surgery and Science, Kyushu University Hospital); T Matoba, MD, PhD.; Y Mukai, MD, PhD. (Department of Cardiovascular Medicine, Kyushu University Hospital); J Koga, MD, PhD.; G Ikeda, MD, PhD. (Department of Cardiovascular Research, Development of Translational Medicine, Kyushu University); K Komori, MD, PhD.; A Kodama, MD, PhD.; A Koyama, MD, PhD. (Division of Vascular Surgery, Department of Surgery, Graduate School of Medicine, Nagoya University Hospital). Project Director: K Egashira, MD, PhD. (Department of Cardiovascular Research, Development and Translational Medicine, Kyushu University). Project Manager: K Nakano, PhD. (Department of Cardiovascular Research, Development and Translational Medicine, Kyushu University). Pharmacokinetic analysis: I Ieiri, PhD. (Chair) M Fukae, PhD. (Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University). Pharmacovigilance: K Todaka, MD., PhD. (Chair); R Taketomi (Activities of Center for Clinical and Translational Research, Kyushu University). Clinical Research Coordinators: M Miura, RN; Y Matsuo, RN (EP-SOGO Co., Ltd.); C Akatsuka (Department of Cardiovascular Medicine, Kyushu University). Monitor: R Shibata, PhD. (EPI Japan Co., Ltd.). Data Managers: K Sakanashi, BE (Chair); S Ishida, LL.B.; K Sumino, RN (Department of Clinical Research Promotion, Kyushu University Hospital). Audit: K Hirano (EPI Japan Co., Ltd.). Statistical analysis: J Kishimoto, MA (Chair, Department of Research and Development of Next Generation Medicine, Kyushu University); H Watanabe, ME; G Eriguchi, MMS (Department of Clinical Research Promotion, Kyushu University Hospital).

Author information

Authors and Affiliations

  1. Department of Cardiovascular Research, Development, and Translational Medicine, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan

    Kaku Nakano Ph.D., Jun-ichiro Koga M.D., Ph.D. & Kensuke Egashira M.D., Ph.D.

Authors
  1. Kaku Nakano Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun-ichiro Koga M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kensuke Egashira M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kensuke Egashira M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

    Yukihito Higashi

  2. Department of Cardiology, Nagoya University, Aichi, Japan

    Toyoaki Murohara

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Nakano, K., Koga, Ji., Egashira, K. (2017). Nanoparticle-Mediated Endothelial Cell-Selective Drug Delivery System. In: Higashi, Y., Murohara, T. (eds) Therapeutic Angiogenesis. Springer, Singapore. https://doi.org/10.1007/978-981-10-2744-4_16

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-2744-4_16

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-2743-7

  • Online ISBN: 978-981-10-2744-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation